US · ANGO
AngioDynamics, Inc.
- Sector
- Healthcare · Medical - Instruments & Supplies
- Headquarters
- Latham, NY 12110
- Website
- angiodynamics.com
Price · as of 2025-05-31
$11.16
Market cap 471.53M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $38.06 | +241.04% |
| Intrinsic Value(DCF) | $3.40 | -69.53% |
| Graham-Dodd Method(GD) | $0.32 | -97.16% |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $13.84 | $38.32 | $3.44 | $11.44 | $2.65 |
| 2012 | $10.70 | $45.95 | $3.41 | $7.23 | $0.00 |
| 2013 | $11.68 | $35.24 | $8.86 | $4.75 | $0.00 |
| 2014 | $14.85 | $51.59 | $4.05 | $5.39 | $0.77 |
| 2015 | $15.42 | $32.33 | $0.00 | $4.67 | $0.00 |
| 2016 | $15.25 | $26.89 | $0.00 | $0.00 | $0.00 |
| 2017 | $16.36 | $33.68 | $0.00 | $3.29 | $0.00 |
| 2018 | $21.35 | $36.25 | $0.00 | $7.09 | $2.91 |
| 2019 | $19.51 | $37.32 | $4.54 | $15.31 | $20.19 |
| 2020 | $9.43 | $47.44 | $0.00 | $0.00 | $76.07 |
| 2021 | $27.18 | $113.76 | $0.00 | $2.10 | $0.00 |
| 2022 | $23.78 | $55.16 | $0.00 | $2.33 | $0.00 |
| 2023 | $8.34 | $37.95 | $0.00 | $0.00 | $0.00 |
| 2024 | $7.44 | $11,657.52 | $0.00 | $0.00 | $7.46 |
| 2025 | $8.51 | $38.06 | $0.00 | $0.32 | $0.00 |
AI valuation
Our deep-learning model estimates AngioDynamics, Inc.'s (ANGO) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $38.06
- Current price
- $11.16
- AI upside
- +241.04%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$3.40
-69.53% upside
Graham-Dodd
$0.32
-97.16% upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| ANGO | AngioDynamics, Inc. | $11.16 | 471.53M | +241% | -70% | -97% | — | -10.26 | 1.91 | 1.19 | 168.52 | — | 3.06 | 53.92% | -13.66% | -11.62% | -17.50% | -30.54% | -11.37% | 0.00 | — | 2.21 | 1.30 | -32.16 | -8192.00% | -376.00% | -5699.00% | -4.18% | -0.13 | -11.17% | 0.00% | 0.00% | 0.48% | -7.33 | -20.07 | 1.00 | 0.98 |
| CGEM | Cullinan Therapeutics, In… | $15.50 | 915.68M | — | — | — | — | -2.79 | 0.79 | — | -0.43 | — | 0.79 | 0.00% | — | — | -32.10% | -214.36% | -30.30% | 0.00 | — | 13.53 | 13.12 | 0.48 | -1572.00% | — | 805.00% | -31.02% | -4.74 | -158.17% | 0.00% | 0.00% | 0.00% | -0.36 | -0.49 | — | 7.79 |
| FULC | Fulcrum Therapeutics, Inc… | $8.38 | 453.45M | +452% | — | — | — | -6.61 | 1.42 | — | -2.03 | -1.04 | 1.42 | 0.00% | — | — | -25.30% | -1230.41% | -23.89% | 0.02 | — | 27.40 | 27.00 | 2.60 | 63750.00% | -10000.00% | 231903.00% | -12.20% | -4.60 | -876.39% | 0.00% | 0.00% | 28.60% | -1.76 | -2.47 | — | 15.27 |
| LAB | Standard BioTools Inc. | $1.13 | 434.56M | +2,535% | -50% | -88% | +606% | -5.60 | 0.99 | 4.92 | -2.77 | — | 0.99 | 49.86% | -109.34% | -87.77% | -16.72% | -23.68% | -12.69% | 0.07 | -3588.65 | 4.19 | 1.86 | 0.92 | -6154.00% | -5108.00% | -4555.00% | -19.69% | -0.69 | -34.48% | 0.00% | 0.00% | 0.00% | -2.82 | -3.18 | 3.08 | 2.09 |
| NMRA | Neumora Therapeutics, Inc… | $3.49 | 583.14M | — | — | — | — | -0.97 | 0.83 | — | 0.26 | -36.29 | 0.83 | 0.00% | — | — | -64.48% | -31666.35% | -59.96% | 0.01 | — | 10.51 | 10.29 | 0.53 | 268.00% | — | 1196.00% | -77.03% | -6.12 | -21987.50% | 0.00% | 0.00% | 0.00% | 0.26 | 0.37 | — | -1.09 |
| OCGN | Ocugen, Inc. | $1.82 | 595.72M | +1,481% | -87% | — | +155% | -3.06 | 5.58 | 40.77 | -2.64 | — | 5.58 | 51.47% | -1350.36% | -1333.02% | -154.01% | -938.91% | -73.55% | 1.10 | — | 2.86 | 2.71 | 0.49 | -2308.00% | -3282.00% | -3723.00% | -27.54% | -1.95 | -780.64% | 0.00% | 0.00% | 0.00% | -2.54 | -3.06 | 34.35 | -5.46 |
| OMER | Omeros Corporation | $12.05 | 854.35M | — | — | — | — | -2.84 | -2.44 | — | -3.58 | -6.51 | -2.44 | 0.00% | — | — | 151.08% | -341.82% | -47.86% | -1.13 | -6.86 | 1.69 | 1.60 | -1.30 | 4362.00% | — | -30050.00% | -33.43% | -1.87 | -300.85% | 0.00% | 0.00% | 36.52% | -3.32 | -3.78 | — | -5.80 |
| RAPT | RAPT Therapeutics, Inc. | $57.98 | 958.84M | — | — | — | — | -0.35 | 0.24 | — | 1.34 | -7.75 | 0.24 | 0.00% | — | — | -77.09% | 654.65% | -62.79% | 0.02 | — | 4.87 | 4.78 | 1.22 | 458.00% | — | -1503.00% | -181.11% | -1.72 | 401.25% | 0.00% | 0.00% | 270.67% | 1.33 | 2.16 | — | -3.97 |
| SNDA | Sonida Senior Living, Inc… | $35.89 | 673.64M | +237% | +24% | -86% | — | -105.95 | 2.82 | 1.14 | 12.59 | — | 3.53 | 89.12% | -4.87% | -0.68% | -11.61% | -2.25% | -0.45% | 5.29 | -0.40 | 0.85 | 0.48 | 8.13 | -8597.00% | 1919.00% | 27150.00% | -7.76% | -0.02 | -4.10% | 0.81% | -85.90% | 0.81% | -66.20 | -36.43 | 3.23 | -0.12 |
| SY | So-Young International In… | $3.11 | 410.96M | +89% | -82% | — | — | -1.42 | 0.45 | 0.57 | 2.91 | — | 0.49 | 61.30% | -42.58% | -40.19% | -27.42% | -57.86% | -19.74% | 0.13 | — | 2.74 | 2.24 | 9.06 | -284375.00% | -209.00% | 20752.00% | -10.56% | -0.04 | -8.18% | 5.22% | -7.40% | 15.49% | 0.18 | 1.27 | -0.08 | 0.45 |
| VREX | Varex Imaging Corporation | $13.17 | 552.08M | +77% | -64% | — | — | -6.94 | 1.03 | 0.57 | 209.03 | -15.31 | 1.86 | 34.39% | -3.29% | -8.32% | -13.87% | -3.65% | -6.01% | 0.85 | -0.78 | 3.43 | 1.67 | 73.40 | 4530.00% | 414.00% | -784.00% | 3.88% | 0.22 | 2.47% | 0.00% | 0.00% | 9.24% | -26.32 | 38.91 | 0.87 | 1.63 |
About AngioDynamics, Inc.
AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and vascular access; and for use in oncology and surgical settings in the United States and internationally. The company provides NanoKnife ablation systems for the surgical ablation of soft tissues; solero microwave tissue ablation systems; and radiofrequency ablation products for ablating solid cancerous or benign tumors. It also offers BioSentry tract sealant systems, IsoLoc Endorectal Balloon's, alatus vaginal balloon packing systems, angiographic catheters, guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits. In addition, the company provides endovascular therapies products in the areas of thrombus management, atherectomy, peripheral products (Core), and venous insufficiency. Additionally, the company offers peripherally inserted central catheters, midline catheters, implantable ports, dialysis catheters, and related accessories and supplies that are used primarily to deliver short-term drug therapies, such as chemotherapeutic agents and antibiotics, into the central venous system under the BioFlo, BioFlo Midline, BioFlo PICC, Xcela PICC, PASV, BioFlo Port, SmartPort, Vortex, LifeGuard, BioFlo DuraMax, and DuraMax names. It sells and markets its products to interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses directly, as well as through distributor relationships. The company was founded in 1988 and is headquartered in Latham, New York.
- CEO
- James C. Clemmer
- Employees
- 748
- Beta
- 0.50
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($3.40 ÷ $11.16) − 1 = -69.53% (DCF, example).